Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  ado-trastuzumab emtansine
Find trials that include:  Any drugs shown
Results 1-15 of 15 for your search:
Start Over
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BO27952, NCI-2013-00507, 2012-000660-22, NCT01641939
A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BO28408, NCI-2014-01818, NCT02131064
A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NSABP FB-10, NCI-2015-00275, NCT02236000
Ado-Trastuzumab Emtansine or Paclitaxel and Trastuzumab in Treating Patients with Stage I HER2-Positive Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-048, NCI-2013-01818, ML28160, NCT01853748
A Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BO29389, NCI-2014-02389, 2014-001237-83, NCT02289833
Trastuzumab Emtansine and Pertuzumab before Surgery in Treating Patients with HER2-Positive Stage II-III Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-409, NCI-2015-00454, NCT02326974
An Extension Study of Trastuzuma Emtansine in Patients Previously Treated With Trastuzuma Emtansine
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TDM4529g, NCI-2009-01154, BO25430, NCT00781612
Ado-Trastuzumab Emtansine in Treating Patients with HER2-Positive Metastatic or Locally Advanced Breast Cancer that Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 7900, NCI-2013-00552, CC-7900, NCT01816035
Palbociclib Isethionate and Ado-Trastuzumab Emtansine in Treating Patients with Recurrent or Metastatic HER2-Positive Breast Cancer
Phase: Phase I
Type: Treatment
Age: 18 to 90
Trial IDs: SCCC-05113, NCI-2014-00821, 042013-042, Mod9_STU 042013-042, NCT01976169
A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ONT-380-004, NCI-2014-00007, NCT01983501
PI3K Inhibitor BYL719 and Trastuzumab Emtansine in Treating Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer Previously Treated with Trastuzumab or Chemotherapy
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 13B06, NCI-2013-02224, STU00087202, NCT02038010
Taselisib and Anti-HER2 Therapy in Treating Patients with Advanced HER2+ Breast Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 15-024, NCI-2015-00627, ML29407, NCT02390427
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment with Ado-Trastuzumab Emtansine in Patients with Metastatic HER2 Positive Breast Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: 14099, NCI-2014-01812, 108543, 114291, 117437, NCT02226276
Start Over